We are joined by John Doupis at the ADA meeting in San Francisco to talk about cardiovascular outcome trials and the results of the highly anticipated REWIND trial, which were presented at this years’ conference.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA.
1. What are the major challenges in designing cardiovascular outcome trials? (0:05)
2. How have the results of the diabetes cardiovascular outcome trials influenced the management of type 2 diabetes? (1:00)
3. How did the REWIND study design differ from other cardiovascular outcome trials? (1:51)
4. What can we expect from the results of the REWIND trial? (2:55)
5. What are your highlights of the ADA 2019 meeting so far? (4:09)
John Doupis is a clinical researcher, lecturer and on the advisory board for Eli Lilly, Novo Nordisk and AstraZeneca.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Diabetes
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
Juliana Chan, EASD 2020 – COVID-19 and type 1 diabetes
We spoke with Prof. Juliana Chan (The Chinese University of Hong Kong, Hong Kong) following her session on COVID-19 and the impact on patients with type 1 diabetes. Questions What key areas of diabetes and COVID-19 were discussed at EASD 2020? (0:05) How do you think the COVID-19 pandemic has affected treatment both now and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!